Suchergebnisse - "Nicholas, Jacqueline"

PubPharm (53)

11

A promising cognitive screener in multiple sclerosis : The NIH toolbox cognition battery concords with gold standard neuropsychological measures

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Manglani, H. | Fisher, M. | Duraney, E. | +2

12

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Hauser, S. | Cross, A. | Winthrop, K. | +17

13

Employing Connectome-Based Models to Predict Working Memory in Multiple Sclerosis

enthalten in: Brain connectivity | 2022

von Manglani, H. | Fountain-Zaragoza, S. | Shankar, A. | +2

14

Burden of Relapsing-Remitting Multiple Sclerosis on Workers in the US: A Cross-sectional Analysis of Survey Data

enthalten in: ResearchSquare.com | 2022

von Nicholas, J. | Electricwala, B. | Lee, L. | +1

15

Burden of Relapsing-Remitting Multiple Sclerosis on Workers in the US: A Cross-sectional Analysis of Survey Data

enthalten in: ResearchSquare.com | 2022

von Nicholas, J. | Electricwala, B. | Lee, L. | +1

16

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial

enthalten in: The Lancet. Neurology | 2022

von Foley, J. | Defer, G. | Ryerson, L. | +98

CommentIn: Lancet Neurol. 2022 Jul;21(7):579-581. - PMID 35483388

17

Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab

enthalten in: Multiple sclerosis and related disorders | 2022

von Nicholas, J. | Gudesblatt, M. | Garabedian, M. | +6

18

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Cohen, J. | Bermel, R. | Grossman, C. | +13

19

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis : APLIOS, a randomized phase-2 study

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Bar-Or, A. | Wiendl, H. | Montalban, X. | +30

20

Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy

enthalten in: Multiple sclerosis journal - experimental, translational and clinical | 2022

von Nicholas, J. | Edwards, N. | Edwards, R. | +4